Scholarlink

<p>Short QT Syndrome type 3 (SQTS3) is an inherited disorder marked by an abnormally short QT interval on ECG and a high risk of life-threatening arrhythmias, for which effective targeted therapies are lacking. SQTS3 is caused by Kir2.1 mutations that enhance the outward component of the strong inward rectifier potassium current (I<sub>K1</sub>), disrupting its normal voltage-dependent regulation and severely abbreviating the cardiac action potential. Using a mouse model of SQTS3 carrying the Kir2.1<sup>M301K</sup> mutation, we examine whether administration of polyamines, the fundamental blockers of Kir2.1 channels, could restore the normal QT interval and prevent arrhythmia. Male mutant mice display reduced I<sub>K1</sub> rectification, reduced sodium channel function, QT interval shortening, and a high susceptibility to induced ventricular tachycardia. Here, we show that systemic polyamine administration restores strong I<sub>K1</sub> rectification, rescues sodium current density, prolongs action potential duration and QT interval, and significantly reduces arrhythmia inducibility, identifying a potential therapeutic approach for SQTS, a life-threatening disease.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Repurposing polyamines to prevent life-threatening arrhythmias in Short QT Syndrome type 3

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月20日

查看全文
  • Ana I. Moreno-Manuel,
  • Francisco M. Cruz,
  • Álvaro Macías,
  • Eva Cabrera-Borrego,
  • José Jalife

摘要

Short QT Syndrome type 3 (SQTS3) is an inherited disorder marked by an abnormally short QT interval on ECG and a high risk of life-threatening arrhythmias, for which effective targeted therapies are lacking. SQTS3 is caused by Kir2.1 mutations that enhance the outward component of the strong inward rectifier potassium current (IK1), disrupting its normal voltage-dependent regulation and severely abbreviating the cardiac action potential. Using a mouse model of SQTS3 carrying the Kir2.1M301K mutation, we examine whether administration of polyamines, the fundamental blockers of Kir2.1 channels, could restore the normal QT interval and prevent arrhythmia. Male mutant mice display reduced IK1 rectification, reduced sodium channel function, QT interval shortening, and a high susceptibility to induced ventricular tachycardia. Here, we show that systemic polyamine administration restores strong IK1 rectification, rescues sodium current density, prolongs action potential duration and QT interval, and significantly reduces arrhythmia inducibility, identifying a potential therapeutic approach for SQTS, a life-threatening disease.